Cagrilintide + Semaglutide (10 mg Blend) Dosage Protocol

Quickstart Highlights

Cagrilintide + Semaglutide is a dual‑agonist combination blending an amylin analog (cagrilintide) with a GLP‑1 receptor agonist (semaglutide). Clinical trials demonstrate superior weight reduction versus either agent alone, with the combination targeting complementary satiety pathways^[1]^[2]. This educational protocol presents a once‑weekly subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL total (1.67 mg/mL each peptide).

Typical weekly range: 0.25–2.4 mg of each peptide once weekly (gradual titration over 16+ weeks).

Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 16.7 mcg each peptide on a U‑100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days; avoid freeze–thaw cycles.

Dosing & Reconstitution Guide

Educational guide for reconstitution and weekly dosing

Standard / Gradual Titration (3 mL = ~3.33 mg/mL total)

Route: Subcutaneous injection. Frequency: Once weekly^[1]^[3].

Week/Phase	Dose per Peptide (mcg / mg)	Units (mL)
Weeks 1–4	250 mcg (0.25 mg) each	15 units (0.15 mL)
Weeks 5–8	500 mcg (0.50 mg) each	30 units (0.30 mL)
Weeks 9–12	1000 mcg (1.0 mg) each	60 units (0.60 mL)
Weeks 13–16	1700 mcg (1.7 mg) each	102 units (1.02 mL)
Week 17+	2400 mcg (2.4 mg) each	144 units (1.44 mL)

Note: Each dose delivers equivalent amounts of both cagrilintide and semaglutide (e.g., 0.25 mg cagrilintide + 0.25 mg semaglutide at Week 1). The 2.4 mg target mirrors clinical trial protocols^[1]^[2].

Reconstitution Math

Vial contents: 5 mg cagrilintide + 5 mg semaglutide = 10 mg total blend

Add: 3.0 mL bacteriostatic water

Concentration: 10 mg ÷ 3.0 mL = 3.33 mg/mL total (1.67 mg/mL each peptide)

Per unit (U‑100 syringe): 3333 mcg/mL × 0.01 mL = 33.3 mcg total per unit (16.7 mcg each peptide)

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until fully dissolved (do not shake).

Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 30 days^[7].

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–16 week weekly protocol with gradual titration.

Peptide Vials (Cagrilintide + Semaglutide, 10 mg blend each):

8 weeks ≈ 1 vial (~6 mg total used)
12 weeks ≈ 2 vials (~14 mg total used)
16 weeks ≈ 3 vials (~27.6 mg total used)

Insulin Syringes (U‑100):

Per week: 1 syringe (once weekly)
8 weeks: 8 syringes
12 weeks: 12 syringes
16 weeks: 16 syringes

Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.

8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
12 weeks (2 vials): 6 mL → 1 × 10 mL bottle
16 weeks (3 vials): 9 mL → 1 × 10 mL bottle

Alcohol Swabs: One for the vial stopper + one for the injection site each week.

Per week: 2 swabs
8 weeks: 16 swabs
12 weeks: 24 swabs
16 weeks: 32 swabs → recommend 1 × 100‑count box

View Supplier

Protocol Overview

Concise summary of the once‑weekly regimen.

Goal: Support significant weight reduction through dual amylin + GLP‑1 receptor agonism^[1]^[2].

Schedule: Weekly subcutaneous injections for 16+ weeks (maintenance thereafter).

Dose Range: 0.25–2.4 mg each peptide weekly with gradual titration.

Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL total) for accurate unit measurements.

Storage: Lyophilized frozen; reconstituted refrigerated; use within 30 days.

Research Disclaimer

Cagrilintide + Semaglutide (10mg Blend Vial) Dosage Protocol